www.marketwired.com/press-release/...ng-otcbb-rgbp-1996855.htm
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy
Company Developing Drug Candidate to Potentially Augment HemaXellerate Therapy for Treating Aplastic Anemia
SAN DIEGO, CA--(Marketwired - Mar 3, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.....................